Study on Mosunetuzumab for Patients with Newly Diagnosed Extranodal Marginal Zone Lymphoma

Inclusion Criteria

• Adults aged 18 years or older.
• Able and willing to sign a consent form and follow the study protocol.
• Diagnosed with EMZL in stages I-IV.
• Have not received any prior treatment for EMZL.
• Participants with H. pylori-positive gastric EMZL who have been treated with antibiotics may be eligible if the lymphoma is confirmed after treatment.
• Participants previously treated with localized therapy (like radiation or surgery) but not systemic therapy, and have recurrent disease, are eligible if confirmed as MZL.
• Must have measurable disease by scans or specific criteria for skin, gastric, or conjunctival EMZL.
• Willing to provide a tissue biopsy or have a recent biopsy available.
• Must meet certain criteria for starting treatment, such as organ function risk, multiple large lymph nodes, large tumor mass, specific symptoms, or blood cell issues.
• Life expectancy of more than 3 months.
• Good overall health with a performance status score of 0 to 2.
• Adequate blood, liver, and kidney function based on specific tests.
• Willing to avoid pregnancy during the study and for at least 90 days after the last dose.

Exclusion Criteria

• Evidence of transformation to a more aggressive lymphoma like DLBCL.
• History of central nervous system lymphoma or leptomeningeal disease.
• Need for immediate reduction of tumor size.
• Previous or concurrent cancer treatments.
• Use of certain immunosuppressive medications recently.
• Previous stem cell transplant or CAR-T therapy.
• Active graft versus host disease.
• Not fully recovered from major surgery.
• Other cancers within the last 3 years, except certain non-threatening types.
• Uncontrolled medical conditions or active infections.
• Recent live vaccine or need for one during the study.
• HIV infection or history of organ transplantation.
• Severe allergic reactions to certain medications.
• Significant heart or lung disease.
• Active hepatitis B or C infection.
• History of autoimmune diseases, unless well-controlled or specific conditions.
• Recent positive COVID-19 test.